OKYO Pharma applies for the go-ahead for phase II trial of its dry eye disease treatment
The study is expected to get underway in the first quarter of next year
Company
OKYO Pharma Ltd
NASDAQ:OKYO
OKYO Pharma Ltd. is an emerging clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. The company is committed to addressing significant unmet medical needs through innovative science, targeted therapeutic approaches, and a disciplined clinical and regulatory development strategy.
103 stories · page 6 of 6
OKYO Pharma to work with AmbioPharm on dry eye IND filing
A US filing is expected in the final quarter of 2022
Okyo Pharma to focus on dry eye treatment in coming year
The group also plans to initiate a Phase 2 trial in the first quarter of 2023